AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.260
-0.010 (-0.79%)
Dec 20, 2024, 4:00 PM EST - Market closed
AN2 Therapeutics Employees
AN2 Therapeutics had 41 employees as of December 31, 2023. The number of employees increased by 5 or 13.89% compared to the previous year.
Employees
41
Change (1Y)
5
Growth (1Y)
13.89%
Revenue / Employee
n/a
Profits / Employee
-$1,480,415
Market Cap
37.65M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 41 | 5 | 13.89% |
Dec 31, 2022 | 36 | 14 | 63.64% |
Dec 31, 2021 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Neuronetics | 203 |
Enzo Biochem | 136 |
OncoCyte | 46 |
Envoy Medical | 34 |
SCYNEXIS | 29 |
Elevation Oncology | 29 |
Aileron Therapeutics | 15 |
CalciMedica | 12 |
ANTX News
- 5 weeks ago - AN2 Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 5 weeks ago - AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline - Business Wire
- 2 months ago - AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria - Business Wire
- 4 months ago - AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
- 4 months ago - AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan - Business Wire
- 4 months ago - AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 4 months ago - AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease - Business Wire
- 7 months ago - AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights - Business Wire